PMS and PMDD share the same trigger — the falling estrogen and progesterone of the luteal phase — and the same timing in the cycle, which is why the two are so often confused. The difference lies entirely in severity, functional impact and diagnostic classification. PMS is common (roughly three in four women), mostly physical (bloating, breast tenderness, fatigue, food cravings) with some mood symptoms (irritability, mild low mood), manageable with self-care and a hot-water-bottle week, and never quite tips into clinical depression criteria.

PMDD is uncommon (3 to 8 percent of women), severe, and dominated by psychological and emotional symptoms (deep sadness or hopelessness, marked anxiety, sharp mood swings, persistent anger, feelings of being out of control) alongside the physical ones. It meets the criteria for clinical depression during the luteal phase, lifts within two to three days of the period starting, and returns again in the next cycle. It is the cyclical, predictable, severe-then-better-then-severe-again pattern that distinguishes PMDD from major depression or generalised anxiety disorder. The DSM-5, the standard psychiatric diagnostic manual used worldwide and in Indian psychiatry, lists PMDD as a depressive disorder in its own right — a recognition that decisively settles the question of whether PMDD is real.

The third clue is functional impact. PMS is a week of mild inconvenience that work, family and relationships absorb without much trouble. PMDD reshapes the luteal week — missed deadlines, work mistakes, fights with partner or children, withdrawal from friends, cancelled social plans, in severe cases self-harm urges or suicidal thoughts — and then lifts as the period starts. If the same pattern of disability repeats two and three months in a row in the luteal phase only, the right next step is a psychiatric assessment for PMDD.

PMDD has a very specific and reproducible time signature on the cycle. Symptoms begin in the luteal phase — the second half of the cycle, roughly from ovulation around day 14 to the start of the next period — and tend to peak in the final 5 to 7 days before the bleed. They lift sharply once the period starts, usually within 2 to 3 days, and the woman is symptom-free or close to it during the follicular phase from the end of the period to ovulation. The next cycle then repeats the same pattern.

This luteal-only pattern is what makes PMDD different from depression and anxiety disorders, which are present most of the time and not driven by the cycle. It is also what makes the daily symptom diary so central to diagnosis: only a two-to-three-cycle diary that maps mood, anxiety, anger, fatigue and physical symptoms day by day can confirm the cyclical pattern that PMDD requires. A woman who is low for three weeks of the month and a little worse in the fourth probably has depression with premenstrual worsening, not PMDD; a woman who is well for two weeks and disabled in the next two has the PMDD pattern.

Three real-world implications follow. First, tracking matters more than memory — most women under-report the well weeks and over-report the bad ones because the contrast is so dramatic. Second, partners and family often see the pattern before the woman does, which is one reason involving them in the diary and the gynec visit helps. Third, the same hormonal trigger means PMDD will tend to flare around any event that disrupts the cycle — postpartum, perimenopause, stopping or starting hormonal contraception — and it does not simply go away with age or with childbirth.

• Severe sadness or hopelessness — a deep low mood that goes well beyond ordinary disappointment and that the woman recognises as out of character and out of proportion.
• Marked anxiety or tension — restlessness, a sense of being on edge, racing thoughts and a feeling of impending dread without a specific trigger.
• Marked mood swings and crying spells — sudden shifts from sad to angry to tearful within hours, often without an external trigger, and crying that feels uncontrollable.
• Persistent anger or irritability and increased interpersonal conflict — short fuse, snapping at partner, children or colleagues, with fights that the woman would not have started in the follicular phase.
• Lack of interest in usual activities — work, hobbies, friendships and sex feel flat and pointless for the luteal week, and re-engage as the period starts.
• Difficulty concentrating, brain fog and indecision — mistakes at work, forgotten appointments, an inability to follow a meeting or finish a familiar task.
• Fatigue and low energy — tiredness that sleep does not refresh, often described as bone-deep heaviness or moving through treacle.
• Appetite changes — strong cravings (often for carbohydrates, sweets or salty food) or binging episodes, and sometimes the opposite of reduced appetite.
• Sleep disturbance — insomnia, frequent night waking or, less commonly, sleeping much more than usual without feeling rested.
• Feeling overwhelmed or out of control — a sense that ordinary demands of work and family are unmanageable and that one cannot trust one's own reactions.
• Physical symptoms — breast tenderness, bloating, joint or muscle pain, headache, weight gain and a feeling of being puffy or swollen.
• Diagnosis requires at least five of the above symptoms during the luteal phase of most cycles in the previous year, with at least one being a mood symptom (sadness, anxiety, mood swings or anger), confirmed by a prospective two-to-three-cycle daily diary.

There is no blood test or scan for PMDD. The diagnosis rests on a careful history and a prospective daily symptom diary, ideally kept across two to three menstrual cycles. The diary is non-negotiable because the same symptoms — sadness, anxiety, anger, fatigue — are also features of depression, anxiety, thyroid dysfunction and several other conditions, and only the cyclical luteal-only pattern distinguishes PMDD from these.

A simple usable diary rates four to six symptoms (mood, anxiety, irritability, energy, sleep, physical) on a 0 to 3 scale each evening, alongside the day of the cycle. Free templates such as the Daily Record of Severity of Problems (DRSP) are widely used and can be downloaded as PDF or used inside several period-tracking apps. Two clean cycles in which symptoms are at least 30 percent worse in the luteal week compared to the follicular weeks, and which lift within 2 to 3 days of the period, are usually enough for a confident diagnosis.

The clinician — usually a gynecologist with mental-health interest or a psychiatrist — then adds a baseline work-up to rule out look-alike conditions. TSH (thyroid), CBC (anaemia), vitamin D, vitamin B12, prolactin and sometimes a depression screening tool such as PHQ-9 are commonly done. A pregnancy test is taken if relevant. Once look-alikes are ruled out and the diary confirms the cyclical pattern, the diagnosis is made on DSM-5 criteria and a treatment plan is built jointly with the woman, almost always starting with lifestyle changes and, depending on severity, adding therapy and medication in parallel.

PMDD is widely under-recognised in India for a stack of overlapping reasons. The first is awareness — both among women and among general practitioners. PMDD does not feature in routine medical school teaching to the same depth as PMS or depression, the lay press rarely covers it, and most women have simply never heard the term. The second is cultural framing — the luteal-week symptoms are often dismissed at home as drama, attention-seeking, weakness of character or 'her usual hormones'; in older women they get relabelled as early menopause; in younger women as just bad PMS.

The third is the shortage of trained clinicians. There are very few gynecologists or psychiatrists in India who actively look for PMDD, ask about cycle-related mood patterns, or hand the patient a daily diary template. Most women who do reach a doctor with mood symptoms get assessed for generalised depression or anxiety, which often leads to a continuous-SSRI prescription that helps partially but misses the cyclical optimisation that PMDD-specific treatment offers. The fourth is the cost-and-time barrier of repeated visits; a daily diary plus two follow-up visits feels expensive for a complaint that families dismiss as not serious. The fifth is the suicidality risk itself — women in a PMDD-bad week often hide the worst symptoms because they feel ashamed or because they fear hospitalisation.

The clinical consequence is that roughly 1 in 20 Indian women has untreated PMDD that drives recurrent marital conflict, parenting strain, missed work and, in the most severe weeks, suicidal thoughts. The good news is that PMDD responds very well to treatment when it is correctly diagnosed. The opening is to know the term, track the cycle for two to three months, and take the diary to a gynec or psychiatrist who is willing to look at it; the rest follows.

• Regular aerobic exercise — 30 minutes of brisk walking, cycling, swimming or dance most days improves mood, reduces anxiety and reduces PMDD symptom severity in most studies; the effect is biological (endorphin and serotonin) as well as behavioural.
• Reduce caffeine, alcohol and refined sugar — caffeine amplifies anxiety, alcohol disrupts sleep and worsens mood the next day, and refined-sugar spikes drive irritability and energy crashes; aim for under 200 mg caffeine per day in the luteal week and limit alcohol to occasional.
• Calcium 1,200 mg and vitamin D — the best-studied supplement combination for PMS and mild PMDD; aim for calcium-rich foods (milk, curd, paneer, ragi, sesame) and a daily supplement if dietary intake is low, with vitamin D titrated to a serum level above 30 ng/mL.
• Magnesium 200 to 400 mg daily — reduces bloating, breast tenderness, fatigue and mood symptoms in trials; magnesium glycinate or citrate are usually better tolerated than oxide; food sources include leafy greens, nuts, seeds, whole grains.
• Vitamin B6 50 to 100 mg daily — modest evidence for reducing PMS and PMDD mood symptoms; cap at 100 mg per day because higher doses can cause peripheral nerve symptoms with long-term use.
• Stress management — daily yoga, pranayama, meditation, journaling or guided breathing reduce luteal-week symptom intensity; apps such as InnerHour and free YouTube guided meditations make this accessible at home.
• Adequate sleep — 7 to 9 hours per night with a consistent bedtime; protect sleep in the luteal week especially by reducing screen time after 9 pm and avoiding late-night caffeine.
• Track and plan around the cycle — schedule demanding meetings, difficult conversations and high-stakes decisions in the follicular phase when possible, and protect the luteal week with lighter loads, lower expectations and more rest.

Cognitive behavioural therapy (CBT) is the most evidence-based talk therapy for PMDD and is typically delivered as a structured 8 to 12 session course with a clinical psychologist. CBT does not change the underlying hormonal trigger, but it changes the way the woman thinks about and responds to the luteal-week symptoms, which dramatically reduces functional disability. Sessions typically work on three threads: identifying and re-framing catastrophic thoughts that show up only in the luteal week ('my marriage is ending', 'I am a failure', 'I will lose my job'), behavioural activation to keep doing essential and rewarding activities even when motivation drops, and communication skills for the luteal week (pausing before responding, naming the symptom rather than blaming the person).

Couples therapy or a single joint session with the partner is often added because the conflict that PMDD generates in the luteal week is one of its biggest functional impacts. A short course teaches the partner how to recognise the pattern, not take cycle-driven anger personally, and provide structured support rather than escalating the conflict. The combined effect of CBT for the woman and one to three educational sessions for the partner often delivers more functional improvement than medication alone.

In India CBT is available in person at most large cities (₹1,000 to ₹3,500 per session in private practice) and online through platforms such as Vandrevala, Sahaj, MannMukti, Amaha (formerly InnerHour) and YourDOST for a fraction of the cost. Government tertiary centres including NIMHANS Bangalore and the AIIMS Department of Psychiatry offer subsidised therapy, with longer waiting lists. eSanjeevani, the government telepsychiatry platform, offers free first-line consultation that can refer on to CBT and medication where needed.

Selective serotonin reuptake inhibitors (SSRIs) are the first-line medication for moderate to severe PMDD and have a strong evidence base across many randomised trials. Two SSRIs are particularly well studied for PMDD: sertraline (brand names Daxid, Zoloft) at 25 to 100 mg daily and fluoxetine (brand name Prozac, Fludac) at 20 mg daily. Other SSRIs (escitalopram, paroxetine) are also used. Unlike in depression where SSRIs take 4 to 6 weeks to start working, in PMDD they often help within the first one to two cycles.

There are two dosing strategies. The first is continuous dosing, where the SSRI is taken every day; this gives the steadiest symptom control and is preferred when symptoms extend beyond the luteal week or when adherence to a luteal-only protocol is difficult. The second is luteal-only dosing, where the SSRI is started around day 14 of the cycle (at ovulation) and stopped on day one of the next period; this option works particularly well for sertraline and fluoxetine, exposes the woman to medication for only half the month, reduces side-effect days, and is often preferred when symptoms are tightly confined to the luteal phase.

Side effects are typically mild and settle within two weeks: nausea, headache, sleep disturbance and reduced libido are the commonest; rarer side effects include weight change and sexual dysfunction. Indian generics make this an affordable option — sertraline 50 mg tablets cost roughly ₹100 to ₹300 per month and fluoxetine 20 mg costs ₹100 to ₹250 per month at most chemists. SSRIs must be prescribed and monitored by a psychiatrist or a gynec with mental-health training; they are not for self-medication. Other medication options that the doctor may consider are combined oral contraceptives in selected women (see next section), spironolactone (Aldactone) 50 to 100 mg daily when fluid retention and breast tenderness are dominant, and in rare severe treatment-resistant cases GnRH agonist therapy with add-back estrogen-progestin under specialist supervision.

Combined oral contraceptive pills can help PMDD in some women by suppressing ovulation and flattening the hormonal swings that drive symptoms. The evidence is strongest for combined pills that contain drospirenone (brand names Yaz, Yasmin, Yasminelle), particularly when taken continuously (skipping the placebo week) or in a 24/4 regimen rather than the standard 21/7. Drospirenone has mild diuretic and anti-androgen effects that seem to help mood-related and physical PMDD symptoms specifically.

Two practical points are worth knowing. First, the response is variable: some women find drospirenone-containing pills dramatically helpful, others find that any combined pill worsens mood symptoms or causes their own side effects. The honest expectation is a three-cycle trial with continued diary tracking to see whether it works for the individual. Second, the pill is not first line for women who already have a personal history of major depression, bipolar disorder or migraine with aura, where the SSRI route is usually preferred and where some combined pills are contraindicated.

In India drospirenone-containing pills are widely available at ₹250 to ₹600 per month under brand names Yamini, Krimson 35 (drospirenone with ethinyl estradiol), and Yaz; standard combined pills (Mala-D, Triquilar) are also options though they do not have the same PMDD-specific evidence. As with SSRIs, the pill needs a doctor's prescription and a screening for the standard combined-pill contraindications (smoking over 35, history of clot, uncontrolled blood pressure, migraine with aura). For some women the eventual answer is a combined pill plus a low-dose SSRI; for others, lifestyle plus CBT is enough; the right answer is whatever the diary and the woman together arrive at.

• iCall — 9152987821 — free and confidential phone, email and chat counselling run by TISS Mumbai, open 8 am to 10 pm Monday to Saturday, multilingual including Hindi, English, Marathi and several South Indian languages.
• Vandrevala Foundation Helpline — 1860-266-2345 or 1800-2333-330 — free 24x7 confidential mental-health helpline with trained counsellors and onward referral to psychiatrists where needed.
• Telemanas — 14416 (or 1-800-891-4416) — the Ministry of Health and Family Welfare's free 24x7 tele mental-health service, available in 20 Indian languages, with onward referral into the public mental-health system.
• NIMHANS Centre Helpline (Bangalore) — 080-46110007 — the National Institute of Mental Health and Neurosciences runs a 24x7 helpline alongside its out-patient services and is one of India's most specialised centres for women's mental health.
• KIRAN Mental Health Helpline — 1800-599-0019 — Ministry of Social Justice and Empowerment 24x7 toll-free helpline in 13 Indian languages.
• AIIMS New Delhi — Department of Psychiatry and the Perinatal and Adolescent Female (PFA) clinic offer specialist assessment of PMDD and other women's mental-health conditions; appointments through the AIIMS OPD booking system.
• Sahaj and Vandrevala counselling platforms — paid and free counselling sessions; useful first contact when stigma blocks an in-person visit.
• eSanjeevani — the government national telemedicine service offers free telepsychiatry consultations; useful first step for women in small cities and rural areas where in-person psychiatrists are scarce.
• Online private platforms — Amaha (formerly InnerHour), Mfine, Practo, Manastha and YourDOST offer paid online therapy and psychiatrist consultations at predictable per-session fees and are useful when privacy or scheduling matters.

• Suicidal thoughts with a plan, a method or a timeline — call Telemanas 14416 or the national emergency number 112 the same hour and go to the nearest hospital emergency department with a family member; do not be alone.
• Strong urges to self-harm (cutting, burning, overdose) — call Vandrevala 1860-266-2345 or iCall 9152987821 immediately and arrange a same-day psychiatric assessment; remove easy access to medication, sharps and other means until the luteal week passes and a plan is in place.
• Severe depressive symptoms — inability to get out of bed for two or more days, inability to eat or look after children, complete loss of interest in everything — same-day psychiatric assessment, in person if available or via eSanjeevani if not.
• Complete inability to function — missed work for several days in a row, escalating fights with partner, children frightened by mood swings — bring forward the next gynec or psychiatry appointment and consider whether continuous-dosing SSRIs or hospitalisation are needed in the short term.
• Postpartum onset or severe worsening of PMDD after childbirth — same-week assessment with a perinatal psychiatrist because postpartum PMDD can overlap with postpartum depression and needs urgent specialist input.
• PMDD plus a personal or family history of bipolar disorder — do not start SSRIs without psychiatric supervision because they can occasionally precipitate a manic episode in vulnerable women; the safer first step is a psychiatrist consultation, not a pharmacy.

• Myth: PMDD is just bad PMS. Fact: PMDD is a distinct DSM-5 depressive disorder, affects 3 to 8 percent of women rather than the 75 percent who have some PMS, and is severe enough to derail work, marriage and parenting in ways PMS never does.
• Myth: PMDD is mental weakness or attention-seeking. Fact: PMDD is a hormone-mediated neurochemical condition in which the brain's serotonin system responds abnormally to the normal estrogen and progesterone shifts of the cycle; the woman is no more responsible for it than for asthma or thyroid disease.
• Myth: PMDD will go away after marriage or after a baby. Fact: PMDD often persists across the reproductive years, can flare postpartum and again during perimenopause, and only reliably resolves at menopause; treatment is the right answer, not waiting.
• Myth: Only Western women get PMDD. Fact: PMDD is a biological condition that exists at the same prevalence globally; it is simply more often diagnosed in Western countries where awareness is higher, and more often dismissed or mislabelled elsewhere.
• Myth: Birth control alone will fix everything. Fact: combined pills with drospirenone help some women, particularly with physical and some mood symptoms, but they are not first line for everyone and many women need an SSRI, CBT or both alongside (or instead of) the pill; the diary plus the doctor decides what works for the individual.